vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
ESPR vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $257.2M |
| Net Profit | — | $88.6M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 34.5% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | 54.4% |
| EPS (diluted) | $0.32 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $168.4M | $265.6M | ||
| Q3 25 | $87.3M | $261.6M | ||
| Q2 25 | $82.4M | $260.7M | ||
| Q1 25 | $65.0M | $193.2M | ||
| Q4 24 | $69.1M | $162.9M | ||
| Q3 24 | $51.6M | $150.8M | ||
| Q2 24 | $73.8M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | — | $91.1M | ||
| Q3 25 | $-31.3M | $83.6M | ||
| Q2 25 | $-12.7M | $57.4M | ||
| Q1 25 | $-40.5M | $-9.0M | ||
| Q4 24 | — | $49.6M | ||
| Q3 24 | $-29.5M | $37.3M | ||
| Q2 24 | $-61.9M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 43.2% | ||
| Q3 25 | -11.4% | 39.5% | ||
| Q2 25 | 8.6% | 27.2% | ||
| Q1 25 | -34.0% | -5.0% | ||
| Q4 24 | -6.4% | 38.0% | ||
| Q3 24 | -31.0% | 29.7% | ||
| Q2 24 | 3.5% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | — | 34.3% | ||
| Q3 25 | -35.9% | 31.9% | ||
| Q2 25 | -15.4% | 22.0% | ||
| Q1 25 | -62.2% | -4.7% | ||
| Q4 24 | — | 30.5% | ||
| Q3 24 | -57.2% | 24.7% | ||
| Q2 24 | -83.9% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.32 | $0.97 | ||
| Q3 25 | $-0.16 | $0.84 | ||
| Q2 25 | $-0.06 | $0.57 | ||
| Q1 25 | $-0.21 | $-0.15 | ||
| Q4 24 | $-0.14 | $0.72 | ||
| Q3 24 | $-0.15 | $0.54 | ||
| Q2 24 | $-0.33 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $4.1B |
| Total Assets | $465.9M | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | $956.1M | ||
| Q3 25 | $92.4M | $1.0B | ||
| Q2 25 | $86.1M | $1.2B | ||
| Q1 25 | $114.6M | $1.1B | ||
| Q4 24 | $144.8M | $568.1M | ||
| Q3 24 | $144.7M | $620.9M | ||
| Q2 24 | $189.3M | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $-302.0M | $4.0B | ||
| Q3 25 | $-451.4M | $4.1B | ||
| Q2 25 | $-433.5M | $3.8B | ||
| Q1 25 | $-426.2M | $3.8B | ||
| Q4 24 | $-388.7M | $2.8B | ||
| Q3 24 | $-370.2M | $2.8B | ||
| Q2 24 | $-344.2M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $465.9M | $27.7B | ||
| Q3 25 | $364.0M | $27.5B | ||
| Q2 25 | $347.1M | $27.6B | ||
| Q1 25 | $324.0M | $27.4B | ||
| Q4 24 | $343.8M | $18.7B | ||
| Q3 24 | $314.1M | $18.5B | ||
| Q2 24 | $352.3M | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $290.4M | ||
| Q3 25 | $-4.3M | $116.9M | ||
| Q2 25 | $-31.4M | $105.0M | ||
| Q1 25 | $-22.6M | $-26.4M | ||
| Q4 24 | $-35.0M | $211.0M | ||
| Q3 24 | $-35.3M | $60.7M | ||
| Q2 24 | $-7.2M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $280.0M | ||
| Q3 25 | — | $114.9M | ||
| Q2 25 | — | $98.3M | ||
| Q1 25 | — | $-30.7M | ||
| Q4 24 | — | $200.7M | ||
| Q3 24 | $-35.5M | $56.9M | ||
| Q2 24 | $-7.3M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 105.4% | ||
| Q3 25 | — | 43.9% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 123.2% | ||
| Q3 24 | -68.7% | 37.7% | ||
| Q2 24 | -9.9% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.9% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 6.3% | ||
| Q3 24 | 0.3% | 2.5% | ||
| Q2 24 | 0.1% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
